BridgeBio Pharma (BBIO) Other Non-Current Assets (2018 - 2026)

BridgeBio Pharma (BBIO) has 9 years of Other Non-Current Assets data on file, last reported at $18.6 million in Q1 2026.

• For the quarter ending Q1 2026, Other Non-Current Assets rose 12.11% year-over-year to $18.6 million; the trailing twelve-month figure through Mar 2026 stood at $18.6 million (up 12.11% YoY), and the FY2025 full-year result was $16.7 million, down 8.15% from the prior year.
• Other Non-Current Assets rose to $18.6 million in Q1 2026, from $16.7 million in the prior quarter.
• In the past five years, Other Non-Current Assets ranged from a high of $35.3 million in Q1 2022 to a low of $16.6 million in Q1 2025.
• A 5-year average of $21.9 million and a median of $20.3 million in 2024 frame the typical range for Other Non-Current Assets.
• Across the five-year window, Other Non-Current Assets plunged 41.21% in 2023 and rose 25.78% in 2025, its largest moves.
• Tracing BBIO's Other Non-Current Assets over 5 years: stood at $20.2 million in 2022, then increased by 11.87% to $22.6 million in 2023, then slipped by 19.58% to $18.2 million in 2024, then declined by 8.15% to $16.7 million in 2025, then climbed by 11.42% to $18.6 million in 2026.
• Business Quant data shows BBIO's Other Non-Current Assets at $18.6 million in Q1 2026, $16.7 million in Q4 2025, and $25.5 million in Q3 2025.